LLY
Eli Lilly and Company
LLY has the edge over UTMD overall, supported by stronger modeled upside and stronger fundamentals.
UTMD
Utah Medical Products, Inc.
UTMD trails on the overall score without a compensating advantage in the available component scores.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
UTMD Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Healthy | |
| Healthy | |
| Strong |
UTMD's profitability, cash flow and balance sheet are currently healthy, but its revenue is under pressure.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
UTMD PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 15x | $50.18 | -32% |
| Fair | 20x | $66.55 | -9.6% |
| Current | 22x | $73.63 | — |
| Expensive | 26x | $84.11 | +14% |
Historical ranges are pointers, not guarantees.
UTMD has the edge over LLY in the historical PE scenario, which offers more potential upside but is not a forecast.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
UTMD Forward outlook
There aren't enough analyst estimates for UTMD to show an outlook.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over UTMD on earnings, with more consistent year-over-year improvement.
UTMD Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.28 | -12% |
| Q1 2026 | $3.38 | -11% |
| Q4 2025 | $3.48 | -12% |
| Q3 2025 | $3.54 | -17% |
| Q2 2025 | $3.74 | -14% |
| Q1 2025 | $3.78 | -16% |
| Q4 2024 | $3.95 | -14% |
| Q3 2024 | $4.27 | -8% |
UTMD's earnings per share have fallen from their peak: $3.28 over the past year, against $4.74 in mid-2023.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over UTMD on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over UTMD on profitability, with a higher operating margin.
UTMD Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $8.5M | -14% |
| Q1 2026 | $8.7M | -10% |
| Q4 2025 | $9M | -1.2% |
| Q3 2025 | $9.8M | -1.9% |
| Q2 2025 | $10M | -4.3% |
| Q1 2025 | $9.7M | -14% |
| Q4 2024 | $9.2M | -26% |
| Q3 2024 | $10M | -20% |
UTMD's revenue has slid since its 2022 peak: $9M last quarter, down 14% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 31% | -1.1 points |
| Q1 2026 | 29% | -3.1 points |
| Q4 2025 | 27% | -5 points |
| Q3 2025 | 27% | -6.8 points |
| Q2 2025 | 32% | -1 points |
| Q1 2025 | 32% | -1.8 points |
| Q4 2024 | 32% | 0 points |
| Q3 2024 | 33% | +1.7 points |
UTMD's operating margin was 31% last quarter, down 1.1 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over UTMD on cash flow, with more consistent year-over-year improvement.
UTMD Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $1.2M | -56% |
| Q1 2026 | $3M | -30% |
| Q4 2025 | $3.4M | +15% |
| Q3 2025 | $3.9M | +2.2% |
| Q2 2025 | $2.8M | +6.4% |
| Q1 2025 | $4.3M | -19% |
| Q4 2024 | $2.9M | -44% |
| Q3 2024 | $3.8M | -24% |
UTMD's free cash flow has been positive every quarter for seven years: $11M over the past year, down 17% from the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has 893M diluted shares, down 0.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
UTMD Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -1K shares |
| 1 year | -1.9% | -62K shares |
| 3 years | -13% | -455K shares |
| 5 years | -13% | -471K shares |
| Available history | -15% | -553K shares |
UTMD has the edge over LLY on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $78,000 |
| Q1 2026 | $128,000 |
| Q4 2025 | $994,000 |
| Q3 2025 | $653,000 |
| Q2 2025 | $3.5M |
| Q1 2025 | $3.2M |
| Q4 2024 | $6.7M |
| Q3 2024 | $3.9M |
UTMD spent $2M buying back its own shares over the past year, down 89% from the year before.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
UTMD Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | -6.9x | Net Cash |
| Q1 2026 | -6.4x | Net Cash |
| Q4 2025 | -6.0x | Net Cash |
| Q3 2025 | -5.7x | Net Cash |
| Q2 2025 | -5.3x | Net Cash |
| Q1 2025 | -5.3x | Net Cash |
| Q4 2024 | -5.1x | Net Cash |
| Q3 2024 | -5.0x | Net Cash |
UTMD has the edge over LLY on leverage, with a lower net debt burden relative to earnings.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
UTMD Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.3 | Neutral |
| Stochastic | 45.8 | Neutral |
UTMD's weekly RSI is 56 (neutral) and its Stochastic is 46 (neutral).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
UTMD PE vs Healthcare Sector
| Metric | UTMD | Sector median | Relative |
|---|---|---|---|
| PE | 22x | 26x | 13% below |
| PE % | 68 | 29 | 39 pts above |
UTMD has the edge over LLY on valuation relative to its sector.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY is in an uptrend: it's above all five of its weekly moving averages, and 79% above its 200-week average.
UTMD Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $73.2 | 0.6% above |
| 20 week MA | $71.7 | 2.6% above |
| 50 week MA | $66.9 | 10% above |
| 100 week MA | $62.5 | 18% above |
| 200 week MA | $71.0 | 3.7% above |
UTMD has climbed back above all five of its weekly moving averages, and it's now 3.7% above its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over UTMD on returns for 2026, with the stronger performance.
UTMD Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $108.4 | $85.5 | -21% |
| 2021 | $85.5 | $97.9 | +15% |
| 2022 | $97.9 | $93.6 | -4.4% |
| 2023 | $93.6 | $84.2 | -10% |
| 2024 | $84.2 | $61.9 | -27% |
| 2025 | $61.9 | $56.8 | -8.3% |
| 2026 YTD | $56.8 | $73.6 | +30% |
UTMD has finished four years in a row lower, and it's up 30% so far in 2026.